發(fā)布時間：2018-04-24 01:34

  本文選題：超聲 + 卵巢�。� 參考：《醫(yī)學(xué)綜述》2016年22期

【摘要】：目的探討超聲形態(tài)學(xué)特征、血流動力學(xué)特征及Alaczar超聲評分對良惡性卵巢腫瘤的鑒別診斷價值。方法選取2013年11月至2015年11月大連市婦幼保健院婦科診治的卵巢原發(fā)性腫瘤患者170例,其中卵巢惡性腫瘤85例,卵巢良性腫瘤85例。觀察良惡性卵巢腫瘤的超聲聲像圖特征,比較良惡性卵巢腫瘤Alaczar超聲評分、血流阻力指數(shù)(RI)及中心血流的差異。以病理學(xué)結(jié)果為金標準,觀察Alaczar超聲評分對惡性卵巢腫瘤的診斷效力。結(jié)果卵巢惡性腫瘤Alaczar超聲評分顯著高于卵巢良性腫瘤[(6.27±1.91)分比(3.56±1.02)分],RI顯著低于卵巢良性腫瘤[(0.42±0.12)分比(0.59±0.16)分],其存在中心血流的比例顯著高于卵巢良性腫瘤[54.1%(46/85)比30.6%(26/85)],差異有統(tǒng)計學(xué)意義(P0.05)。臨床分期Ⅲ~Ⅳ期臨床惡性腫瘤Alaczar超聲評分顯著高于臨床分期Ⅰ~Ⅱ期者[(5.91±1.85)分比(6.78±1.98)分],差異有統(tǒng)計學(xué)意義(P0.05)。以手術(shù)病理及穿刺細胞學(xué)結(jié)果為金標準,Alaczar超聲評分對卵巢惡性腫瘤診斷靈敏度、特異度、陽性預(yù)測率、陰性預(yù)測率及準確度分別為90.6%、88.2%、88.5%、90.4%和89.4%,均高于RI(71.8%、52.9%、60.4%、65.2%、62.4%)及中心血流(83.5%、64.7%、70.3%、79.7%、74.1%)。結(jié)論超聲形態(tài)學(xué)特征、血流動力學(xué)特征及Alaczar超聲評分可以為良惡性卵巢腫瘤鑒別診斷提供有價值的信息,其中Alaczar超聲評分價值最高。
[Abstract]:Objective to study the value of ultrasonic morphology, hemodynamics and Alaczar in differential diagnosis of benign and malignant ovarian tumors. Methods from November 2013 to November 2015, 170 cases of primary ovarian tumor diagnosed and treated by Department of Gynecology in Dalian Maternal and Child Health Hospital were selected, including 85 cases of malignant ovarian tumor and 85 cases of benign ovarian tumor. The ultrasonographic features of benign and malignant ovarian tumors were observed, and the differences of Alaczar, RI and central blood flow in benign and malignant ovarian tumors were compared. The diagnostic efficacy of Alaczar ultrasound score on malignant ovarian tumors was observed by using pathological results as gold standard. Results the Alaczar ultrasound score of malignant ovarian tumors was significantly higher than that of benign ovarian tumors [6.27 鹵1.91 vs 3.56 鹵1.02] RI was significantly lower than that of benign ovarian tumors [0.42 鹵0.12 vs 0.59 鹵0.16], and the proportion of central blood flow in malignant ovarian tumors was significantly higher than that in benign ovarian tumors [54.14685 vs 30.6262685]. The Alaczar ultrasound score of clinical malignant tumor in stage 鈪，

本文編號：1794569